-
2024-515300-39-00
4
2024-10-18
METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA OF G
-
2023-509334-19-00
5
2024-10-17
gastro-enteropancreatic neuroendocrine tumors (GEP-NETs)
-
2023-504724-25-00
5
2024-10-16
Primary Myelofibrosis
-
2023-504513-77-00
4
2024-09-16
Adult patients older than 18 years. Patients admitted to the participa
-
2023-506216-40-00
5
2024-08-14
CytoMegaloVirus infections
-
2024-515297-27-00
5
2024-08-14
colon carcinoma
-
2023-503859-10-00
5
2024-08-12
Moderate to Severe Plaque Psoriasis
-
2023-508005-24-00
5
2024-08-01
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
2022-502155-65-00
5
2024-07-30
Extra pulmonary sarcoidosis
-
2024-512872-36-00
5
2024-07-25
obstetric_pathological delivery
-
2023-509905-62-00
5
2024-07-19
Lower limb trauma requiring immobilisation
-
2023-505298-34-00
4
2024-07-18
Patients with dMMR/MSI (non-colorectal/non-endometrial) locally advanc
-
2023-509042-35-01
4
2024-07-18
Adults patients will be included in the hematology departments. Eligib
-
2023-507641-29-00
4
2024-07-15
Locally Advanced or Metastatic Solid Tumors
-
2024-512004-19-01
5
2024-07-02
Head trauma
-
2023-505112-38-00
11
2024-07-01
recently active non-infectious intermediate, posterior, and pan-uveiti
-
2023-508590-89-00
7
2024-06-25
Multiple Myeloma
-
2023-508100-38-00
5
2024-06-24
Advanced Biliary Cancer (ABC)
-
2023-506705-20-00
4
2024-06-14
relapsed or refractory patients with aggressive large B-cell lymphoma
-
2023-505214-23-00
5
2024-06-07
colon carcinoma
-
2023-503499-25-00
6
2024-06-06
Post-operative pain after surgery
-
2023-505436-35-00
5
2024-06-03
Untreated FLIPI 2-5 Follicular Lymphoma
-
2023-507751-30-00
9
2024-05-27
relapsed or refractory multiple myeloma
-
2023-507871-23-00
5
2024-05-27
Relapsed/Refractory Multiple Myeloma